Payment overview · 2025
General Payments
$506.61
21 reported records · 11 companies
Healthcare provider profile · identity verified
Caitlin Copes, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · VICKSBURG, MS · NPI 1326578600
Verified facts
What the public records show
CMS Open Payments records show Caitlin Copes, FNP received $506.61 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.18 | 28.5% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $87.11 | 17.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $69.55 | 13.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.75 | 11.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.37 | 9.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.81 | 4.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.42 | 4.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.73 | 3.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.45 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.73 | 2.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.51 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $506.61 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $144.18 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $87.11 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $69.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $66.79 | 4 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $43.75 | 2 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $27.74 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | 17 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 224 | 39 |
| Furosemide | Furosemide | 178 | 54 |
| Gabapentin | Gabapentin | 160 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 43 |
| Lisinopril | Lisinopril | 134 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 128 | 116 |
| Potassium Chloride | Potassium Chloride | 126 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 46 |
| Metformin Hcl | Metformin Hcl | 105 | 30 |
| Memantine Hcl | Memantine Hcl | 95 | 14 |
| Omeprazole | Omeprazole | 87 | 27 |
| Trazodone Hcl | Trazodone Hcl | 85 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 82 | 33 |
| Methylprednisolone | Methylprednisolone | 78 | 71 |
| Rivastigmine | Rivastigmine Tartrate | 78 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 23 |
| Azithromycin | Azithromycin | 69 | 64 |
| Pregabalin | Pregabalin | 67 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 56 | 21 |
| Alprazolam | Alprazolam | 55 | 19 |
| Meloxicam | Meloxicam | 55 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Losartan Potassium | Losartan Potassium | 53 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 27 |
| Tramadol Hcl | Tramadol Hcl | 52 | 32 |
| Fluconazole | Fluconazole | 51 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 44 |
| Carvedilol | Carvedilol | 46 | 13 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Famotidine | Famotidine | 45 | 19 |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Baclofen | Baclofen | 43 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 39 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 18 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 24 |
| Levofloxacin | Levofloxacin | 34 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 11 |
| Metronidazole | Metronidazole | 32 | 24 |
| Ozempic | Semaglutide | 32 | 17 |
| Sertraline Hcl | Sertraline Hcl | 32 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 13 |
| Nifedipine Er | Nifedipine | 31 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 13 |
| Eliquis | Apixaban | 29 | 12 |
| Simvastatin | Simvastatin | 29 | 13 |
| Cephalexin | Cephalexin | 28 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 24 |
| Clonidine Hcl | Clonidine Hcl | 25 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 14 |
| Glipizide | Glipizide | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 20 |
| Spironolactone | Spironolactone | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 15 |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Metolazone | Metolazone | 17 | 15 |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Naproxen | Naproxen | 13 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $506.61 · 21 records | AstraZeneca Pharmaceuticals LP | AVYCAZ, BREZTRI, DALVANCE, GEMTESA, General - Pain Management, Kerendia, MOUNJARO, QULIPTA, REXULTI, TEFLARO, UBRELVY, Veozah, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error